Research for the progression of encapsulating peritoneal sclerosis

Research Project

Project/Area Number	21591062
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Single-year Grants
Section	一般
Research Field	Kidney internal medicine
Research Institution	Tokai University
Principal Investigator	KAKUTA Takatoshi 東海大学, 医学部, 准教授 (50276854)
Co-Investigator(Kenkyū-buntansha)	TANAKA Reika 東海大学, 医学部, 講師 (10372947)
Project Period (FY)	2009 – 2011
Project Status	Completed (Fiscal Year 2011)
Budget Amount *help	¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000) Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000) Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	ピリドキサミン / 腹膜透析 / 最終糖化産物 / カルボニル化合物 / メチルグリオキサール / 慢性腎不全 / AGE / カルボニルストレス / 被嚢性硬化性腹膜炎(EPS) / 終末化糖産物(AGE)
Research Abstract	This study is to assess the efficacy of pyridoxamine against the peritoneal damage under induced by the peritoneal dialysis fluid. We administered pyridoxamine to the peritoneal damage and renal failure model rat. However, we couldn't prove this efficacy of the drug from some reasons, for example, rather minor damage of the peritoneum. We are currently on the re-experiment. Which intends to induce more damage on the peritoneum raising the dose of methylglyoxal, one of the Glucose degradation products. Concurrently, raising the dose of pyridoxamine to make the effect of pyridoxamine more definite. We also examined the pharmacokinetics of the drug with a small number of chronic renal failure patients on peritoneal dialysis. The pyridoxamine concentration in blood and subsequently, concentration of the drug in the peritoneal dialysis fluid effluent raised.